Moreover, we revealed in vivo that the combination of cisplatin and irradiation, in conjunction with postirradiation anti–PD-1 treatment, exerted antitumor effects in nonirradiated tumors, in which an increase in cytotoxic T cells was observed in the tumor microenvironment. The gene discussed is PDCD1; the disease is neoplasm.